Predictive Oncology Inc
POAI0.774USD
+0.012+1.57%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
6.91MCap. mercado
PérdidaP/E TTM
Más Datos de Predictive Oncology Inc Compañía
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Información de la empresa
Símbolo de cotizaciónPOAI
Nombre de la empresaPredictive Oncology Inc
Fecha de salida a bolsaDec 18, 2009
Director ejecutivoMr. Raymond F. Vennare
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 18
Dirección91 43Rd Street
CiudadPITTSBURGH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal15201
Teléfono14124321500
Sitio Webhttps://predictive-oncology.com/
Símbolo de cotizaciónPOAI
Fecha de salida a bolsaDec 18, 2009
Director ejecutivoMr. Raymond F. Vennare
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nancy Chung-Welch, Ph.D.
Dr. Nancy Chung-Welch, Ph.D.
Independent Director
Independent Director
19.31K
+11.64%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
17.02K
+10.69%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.12K
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nancy Chung-Welch, Ph.D.
Dr. Nancy Chung-Welch, Ph.D.
Independent Director
Independent Director
19.31K
+11.64%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
17.02K
+10.69%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.12K
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 15 de jul
Actualizado: mar., 15 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
0.70%
Geode Capital Management, L.L.C.
0.62%
Nuzum (Charles Lee Sr)
0.29%
St Clair (Gregory Sr)
0.21%
Chung-Welch (Nancy)
0.19%
Other
98.00%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
0.70%
Geode Capital Management, L.L.C.
0.62%
Nuzum (Charles Lee Sr)
0.29%
St Clair (Gregory Sr)
0.21%
Chung-Welch (Nancy)
0.19%
Other
98.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
1.56%
Individual Investor
1.18%
Investment Advisor
0.21%
Endowment Fund
0.11%
Hedge Fund
0.05%
Research Firm
0.01%
Other
96.89%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
44
299.26K
2.93%
-277.17K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
2023Q1
72
429.97K
10.87%
-298.57K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
71.31K
0.8%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
62.93K
0.7%
+11.72K
+22.90%
Mar 31, 2025
Nuzum (Charles Lee Sr)
29.91K
0.33%
+2.01K
+7.22%
Mar 20, 2025
St Clair (Gregory Sr)
21.20K
0.24%
+1.33K
+6.70%
Mar 20, 2025
Chung-Welch (Nancy)
19.31K
0.22%
+2.01K
+11.64%
Mar 20, 2025
UBS Financial Services, Inc.
18.98K
0.21%
+18.98K
--
Mar 31, 2025
Handley (Daniel E)
17.02K
0.19%
+1.64K
+10.69%
Mar 20, 2025
State Street Global Advisors (US)
13.84K
0.15%
--
--
Mar 31, 2025
Carnegie Mellon University
10.36K
0.12%
--
--
Mar 31, 2025
Hawryluk (Matthew)
9.49K
0.11%
--
--
Mar 20, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Fecha
Tipo
Relación
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
